Growth Metrics

Gilead Sciences (GILD) Operating Income Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 81.11%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 3.64%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 12.96%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -203.67%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 11.54%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 14.90%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 2.04%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -42.48%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 14.90%
Dec 31, 2025 -4.35%
Sep 30, 2025 5.45%
Jun 30, 2025 6.83%
Mar 31, 2025 124.77%
Dec 31, 2024 37.66%
Sep 30, 2024 -38.63%
Jun 30, 2024 5.59%
Mar 31, 2024 -51.76%
Dec 31, 2023 -15.28%
Sep 30, 2023 9.44%
Jun 30, 2023 36.77%
Mar 31, 2023 -10.80%
Dec 31, 2022 27.53%
Sep 30, 2022 57.76%
Jun 30, 2022 -5.83%
Mar 31, 2022 -55.51%
Dec 31, 2021 -6.34%
Sep 30, 2021 13.57%
Jun 30, 2021 -0.50%
Mar 31, 2021 10.31%
Dec 31, 2020 57.77%
Sep 30, 2020 -19.33%
Jun 30, 2020 -39.27%
Mar 31, 2020 -13.93%
Dec 31, 2019 -35.35%
Sep 30, 2019 -32.66%
Jun 30, 2019 -18.80%
Mar 31, 2019 -21.65%
Dec 31, 2018 -41.18%
Sep 30, 2018 -22.27%
Jun 30, 2018 -25.95%
Mar 31, 2018 -26.27%
Dec 31, 2017 -46.18%
Sep 30, 2017 3.08%
Jun 30, 2017 -1.21%
Mar 31, 2017 7.37%
Dec 31, 2016 50.06%
Sep 30, 2016 56.49%
Jun 30, 2016 57.85%
Mar 31, 2016 65.54%
Dec 31, 2015 71.89%
Sep 30, 2015 74.90%
Jun 30, 2015 74.38%
Mar 31, 2015 88.63%
Dec 31, 2014 70.90%
Sep 30, 2014 51.35%
Jun 30, 2014 63.11%
Mar 31, 2014 49.98%
Dec 31, 2013 13.01%
Sep 30, 2013 5.44%
Jun 30, 2013 5.14%
Mar 31, 2013 -4.06%
Dec 31, 2012 1.28%
Sep 30, 2012 5.29%
Jun 30, 2012 11.64%
Mar 31, 2012 -0.34%